ASPRE trial: performance of screening for preterm pre‐eclampsia

@article{Rolnik2017ASPRETP,
  title={ASPRE trial: performance of screening for preterm pre‐eclampsia},
  author={Daniel Lorber Rolnik and David Wright and L. C. Poon and Argyro Syngelaki and N O'gorman and Catalina de Paco Matallana and Ranjit Akolekar and Simona Cicero and Deepa Janga and M. Singh and Francisca Sonia Molina and Nicola Persico and Jacques C. Jani and Walter Plasencia and G Papaioannou and Kinneret Tenenbaum-Gavish and Kypros H. Nicolaides},
  journal={Ultrasound in Obstetrics \& Gynecology},
  year={2017},
  volume={50}
}
OBJECTIVE To examine the performance of screening for preterm and term pre-eclampsia (PE) in the study population participating in the ASPRE (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention) trial. [...] Key Method Eligible women with an estimated risk for preterm PE of > 1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg per day) vs placebo from 11-14 until 36 weeks' gestation, which showed that, in the…Expand
Evaluation of a simple risk score to predict preterm pre‐eclampsia using maternal characteristics: a prospective cohort study
  • U. Sovio, Gcs Smith
  • Medicine
  • BJOG : an international journal of obstetrics and gynaecology
  • 2019
TLDR
A simple risk score for preterm pre‐eclampsia is derived based on the model used in the ASPRE trial to compare it with the original ASPRE algorithm, with the NICE Guideline score, and with and without biochemical and ultrasonic predictors. Expand
Comparison of diagnostic accuracy of early screening for pre‐eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE
  • M. Tan, D. Wright, +9 authors K. Nicolaides
  • Medicine
  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2018
To test the hypothesis that the performance of first‐trimester screening for pre‐eclampsia (PE) by a method that uses Bayes' theorem to combine maternal factors with biomarkers is superior to thatExpand
Prediction of preterm pre‐eclampsia according to NICE and ACOG criteria: descriptive study of 597 492 Danish births from 2008 to 2017
TLDR
The incidence of preterm preeclampsia has remained largely unchanged over the last decade in Denmark and Prediction according to maternal risk factors could be improved by addition of moderate-risk factors. Expand
Prediction and prevention of small‐for‐gestational‐age neonates: evidence from SPREE and ASPRE
  • M. Tan, L. Poon, +14 authors K. Nicolaides
  • Medicine
  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2018
To examine the effect of first‐trimester screening for pre‐eclampsia (PE) on the prediction of delivering a small‐for‐gestational‐age (SGA) neonate and the effect of prophylactic use of aspirin onExpand
Screening for pre‐eclampsia at 35–37 weeks' gestation
To examine the performance of screening for pre‐eclampsia (PE) at 35–37 weeks' gestation by maternal factors and combinations of mean arterial pressure (MAP), uterine artery pulsatility indexExpand
Prenatal screening for pre‐eclampsia: Frequently asked questions
TLDR
Combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre‐eclampsia, and the administration of aspirin for the 10% screen‐positive group can lead to a significant reduction in severe and preterm forms of pre‐ eClampsia. Expand
Preterm parturition and pre‐eclampsia: The confluence of two great gestational syndromes
  • A. Jayaram, Charlene H. Collier, James N. Martin
  • Medicine
  • International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 2020
Preterm birth (PTB) and pre‐eclampsia independently, and frequently concurrently, adversely affect the pregnancy outcomes of millions of mothers and infants worldwide each year.
Early screening and prevention of preterm pre‐eclampsia with aspirin: time for clinical implementation
  • D. Rolnik, N. O'gorman, +5 authors F. da Silva Costa
  • Medicine
  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2017
TLDR
An ideal screening test requires identification of women at high-risk of developing severe and early-onset forms of the disease, a high detection rate (DR) with an acceptable false-positive rate (FPR), and the availability of an effective preventive measure. Expand
Local validation and calibration of pre‐eclampsia screening algorithms
  • H. Cuckle
  • Medicine
  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2019
A recent Practice Guideline issued by the International Society of Ultrasound in Obstetrics and Gynecology recommends a combination of a priori factors and pregnancy-specific makers, determined atExpand
Quality assessment of uterine artery Doppler measurement in first‐trimester combined screening for pre‐eclampsia
TLDR
To assess the quality of mean uterine artery (UtA) pulsatility index (PI) measurement in a first‐trimester pre‐eclampsia screening program, a randomised, double-blind, placebo-controlled study is conducted. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
Multicenter screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations
  • N. O'gorman, D. Wright, +14 authors K. Nicolaides
  • Medicine
  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2017
TLDR
To compare the performance of screening for pre‐eclampsia based on risk factors from medical history with the method proposed by The Fetal Medicine Foundation, which uses Bayes' theorem to combine the a‐priori risk from maternal factors, derived by a multivariable logistic model, with the results of various combinations of biophysical and biochemical measurements. Expand
Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre‐eclampsia
TLDR
To determine the performance of screening for pre‐eclampsia (PET) by maternal characteristics and uterine artery pulsatility index (PI) at 11 + 0 to 13 + 6 weeks' gestation, a large number of women with high‐risk pregnancies are surveyed. Expand
Serum pregnancy‐associated plasma protein‐A in the three trimesters of pregnancy: effects of maternal characteristics and medical history
To define the contribution of maternal variables which influence the measured level of maternal serum pregnancy‐associated plasma protein‐A (PAPP‐A) in screening for pregnancy complications.
Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history
TLDR
To define the contribution of maternal variables which influence the measured level of maternal serum placental growth factor (PlGF) in screening for pregnancy complications, and to describe the mechanism behind the observed changes in serum PlGF levels. Expand
Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history
TLDR
To define the contribution of maternal variables that influence the measured mean arterial pressure (MAP) in screening for pregnancy complications, the objective is to establish a baseline for this study and establish a methodology for future studies. Expand
Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history
TLDR
To define the contribution of maternal variables that influence the measured uterine artery pulsatility index (UtA‐PI) in screening for pregnancy complications, the objective was to establish a baseline for this index and establish its significance in pregnancy complications screening. Expand
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
TLDR
Treatment with low‐dose aspirin in women at high risk for preterm preeclampsia resulted in a lower incidence of this diagnosis than placebo, and there were no significant between‐group differences in the incidence of neonatal adverse outcomes or other adverse events. Expand
Competing risks model in screening for preeclampsia by maternal characteristics and medical history.
TLDR
A new model that is based on maternal characteristics and medical history has been developed for the estimation of patient-specific risks for preeclampsia and is an essential first step in the use of Bayes theorem to combine maternal factors with biomarkers for the continuing development of more effective methods of screening for the disease. Expand
Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers
TLDR
A new model has been developed for effective first-trimester screening for PE based on maternal characteristics, biophysical and biochemical markers based on a survival time model for the time of delivery in which Bayes’ theorem was used. Expand
Protocol for Measurement of Mean Arterial Pressure at 11-13 Weeks' Gestation
TLDR
Performance of screening for PE by taking the average of a minimum of two measurements from both arms is comparable to the NHFA protocol. Expand
...
1
2
...